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Acute leukemia often presents with pure chromosomal resolution; thus, aberrations may not be detected by banding cytogenetics.
Here, a case of 26-year-old male diagnosed with T-cell acute lymphoblastic leukemia (T-ALL) and a normal karyotype after
standard GTG-banding was studied retrospectively in detail by molecular cytogenetic and molecular approaches. Besides
fluorescence in situ hybridization (FISH), multiplex ligation-dependent probe amplification (MLPA) and high resolution array-
comparative genomic hybridization (aCGH) were applied. Thus, cryptic chromosomal aberrations not observed before were
detected: three chromosomes were involved in a cytogenetically balanced occurring translocation t(2;9;18)(p23.2;p21.3;q21.33).
Besides a translocation t(10;14)(q24;q11) was identified, an aberration known to be common in T-ALL. Due to the three-way
translocation deletion of tumor suppressor genes CDKN2A/INK4A/p16, CDKN2B/INK4B/p15, andMTAP/ARF/p14 in 9p21.3 took
place. Additionally RB1 in 13q14 was deleted. This patient, considered to have a normal karyotype after low resolution banding
cytogenetics, was treated according to general protocol of anticancer therapy (ALL-BFM 95).
1. Introduction
T-cell acute lymphoblastic leukemia (T-ALL) is a quite rare
and heterogeneous disease, more common in males than in
females. It accounts for 15% of childhood and 25% of adult
ALL cases [1]. Underlying genetic causes of T-ALL are poorly
understood and this is highlighted by the fact that T-ALL is
associated with a normal karyotype in 30–50% of the cases [2,
3]. In abnormal karyotypes recurrent chromosomal aberra-
tions are reported [4]. Regularly, promoter and enhancer ele-
ments of genes involved in T-cell development are juxtaposed
with translocations in close proximity of oncogenes [5, 6].The
most common structural chromosomal abnormalities in T-
ALL are TCR (T-cell receptor) loci rearrangements. Break-
points in 14q11 (TCRA/D) and 7q34 (TCR𝛽) are observed
frequently. Besides, deletions in the long arm of chromosome
6 may be found; the common deleted region involves mainly
subband 6q16; however, candidate gene(s) have not been
formally identified yet [7, 8]. Also tumor suppressor genes
have been seen to be involved in T-ALL [9].
Cryptic structural chromosomal abnormalities are still
a challenge in cytogenetic standard diagnostics of acute
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leukemia. However, many cryptic aberrations have been
identified by molecular cytogenetics already. Examples in
T-ALL are cryptic deletions in 9p21 involving the genes
CDKN2A/INK4A/p16, CDKN2B/INK4B/p15, and MTAP/
ARF/p14 leading to loss of G1 checkpoint control of the cell
cycle or the RB1 locus in 13q14, which also plays a role as
tumor suppressor gene in cell cycle regulation [9].
Here, a case of a young adult T-ALL patient with a novel
cryptic three-way translocation, a reciprocal translocation,
and submicroscopic deletions is reported.
2. Material and Methods
2.1. Clinical Description. A 26-year-old male presented in
1998 initially with a total white blood cell count of 20.2 ×
109/L, hemoglobin of 9.2mmol/L, and platelets of 126 ×
109/L. Bone marrow examination was consistent with T-ALL
having 91% blast cells. According to flow cytometry the
immunophenotype of bone marrow lymphocytes was as
follows: the cells were positive for CD2 (96%), CD8 (96%),
CD4 (92%), CD7 (92%), CD1A (89%), CD10 (87%), CyCD3
(86%), and TdT (85%) and negative for 𝛼F1, 𝛽F1, CD3, CD13,
CD19, CD20, CD24, CD33, CD34, HLA-DR, MPO-7, slg,
TZR-𝛼/𝛽, and TZR𝛾/𝛿. The patient was treated according
to ALL-BFM 95 protocol and died eight months after initial
diagnosis from serious infections and severe complications
while being in complete hematological remission.
2.2. Test Done at Diagnosis. GTG-banding was done accord-
ing to standard procedures. A total of 7 metaphases were
available for cytogenetic evolution derived from unstimu-
lated bone marrow of the patient and were analyzed on
a banding level of 180–250 bands per haploid karyotype
[11] and determined as 46,XY [7, 12]. RT-PCR performed
for TEL/AML1 and BCR/ABL fusion genes was reported to
be negative and fluorescence in situ hybridization (FISH)
analysis carried out according to manufacturer’s instructions
for the same loci was negative (probes used: LSI BCR/ABL
and LSI TEL/AML1, Abbott Molecular/Vysis, Mannheim,
Germany).
2.3. Test Done in Retrospective
2.3.1. Molecular Cytogenetics. FISH was done according to
standard procedures and manufacturer’s instructions for the
following commercially available probes: LSI 13 in 13q14.2
(RB1, Abbott Molecular/Vysis, Mannheim, Germany), LSI
IGH/BCL2 (IGH in 14q32; BCL2 in 18q21, Abbott Molec-
ular/Vysis, Mannheim, Germany), SPEC ALK/2q11 (ALK
in 2p23, Zytovision GmbH, Bremerhaven, Germany), SPEC
p16/CEN9 (p16 in 9p21.3, Zytovision GmbH, Bremer-
haven, Germany), SPEC BIRC3/MALT1 (BIRC3 in 11q22.2,
MALT1 in 18q21.32, Zytovision, Bremerhaven, Germany), and
POSEIDONMLL/MLLT3 (MLL in 11q23.3,MLLT3 in 9p21.3;
Kreatech Diagnostics, Amsterdam, Netherland).
Whole chromosome painting (WCP) probe for chromo-
somes 2, 9, 10, 14, and 18 and bacterial artificial chromo-
some probes (BACs) for chromosomes 2 and 9 (Table 1)
were homemade [13]. The homemade multitude multicolor-
banding (mMCB) and chromosome specific high resolution
array-proven multicolor-banding (aMCB) probe sets were
also applied as previously reported [10, 14, 15].
A total of 10–15 metaphase spreads were analyzed,
using a fluorescence microscope (AxioImager.Z1 mot, Zeiss)
equipped with appropriate filter sets to discriminate between
amaximumof five fluorochromes and the counterstain DAPI
(Diaminophenylindol). Image capturing and processing were
carried out using an ISIS imaging system (MetaSystems,
Altlußheim, Germany).
2.3.2. DNA Isolation. GenomicDNAwas extracted from cells
fixed in acetic acid :methanol (1 : 3) by Puregene DNA Purifi-
cation Kit (Gentra Systems, Minneapolis, MN, USA). DNA
concentration was determined by a Nanodrop spectropho-
tometer. The quality of DNA was checked using agarose gel
electrophoresis. DNA samples extracted from fixed cells of 2
healthymales and 2 healthy females by the samemethodwere
used as reference samples.
2.3.3. Multiplex Ligation-Dependent Probe Amplification
(MLPA). The P377-A1 hematologic malignancies probemix
and SALSA reagents were used for this study (MRC-Hol-
land, Amsterdam, The Netherlands). Amplified probes and
Genescan 500ROX standardwere separated by capillary elec-
trophoresis using a 4-capillary ABI-PRISM 3130XL Genetic
Analyzer (Applied Biosystems, Foster City, USA). Sizing of
peaks and quantification of peak areas and heights were
performed using GeneMarker v1.9 software (Applied Biosys-
tems). A minimum of 4 healthy control samples were includ-
ed in each run.
2.3.4. High Resolution Array-Comparative Genomic Hybridi-
zation (aCGH). aCGH was performed using Agilent Sure-
Print G3 Human Genome microarray 180K (Agilent Tech-
nologies, Santa Clara, CA, USA), an oligonucleotidemicroar-
ray containing approximately 180,000 probes 60-mer with a
17 kb average probe spacing. Genomic DNA of patient was
cohybridized with a male control DNA (Agilent Technolo-
gies, Santa Clara, CA, USA). Labeling was performed using
Agilent Genomic DNA enzymatic labeling kit (Agilent)
according to the manufacturers’ instructions. After hybridi-
zation, the aCGH slide was scanned on an Agilent scanner
and processed with Feature Extraction software (v10.7) and
results were analyzed using Cytogenomics (v2.9.1.3) using
ADM2 as aberration algorithm.
3. Results of Retrospective Analysis
As an initial test of retrospective analysis a genome wide
FISH-banding applying mMCB was performed. Thereby, a
previously unrecognized reciprocal and apparently balanced
translocation between the three chromosomes 2, 9, and
18 was identified. Besides a known recurrent translocation
of chromosomes 10 and 14 was recognized and the kary-
otype was suggested as 46,XY,t(2;9;18)(p23.2;p21.3;q21.33),
t(10;14)(q24;q11) (Figure 1). aMCB and WCP probes as
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Table 1: (a) Probes used for characterization of the three-way translocation, their location, and obtained results. (b) Probes used for
characterization of the in aCGH detected deletions, their location, and obtained results.
(a)
Cytoband Location [hg19] Probe Result for derivative chromosomes
2p24.3 chr2: RP11-119F22 Signal on der(9); no split signal
16,014,784–16,140,647
2p23.3 chr2: RP11-106G13 Signal on der(9); no split signal
26,967,697–27,136,688
2p23.2 chr2: SPEC ALK Signal on der(9); no split signal
29,415,640–29,447,593
9p22.1 chr9: RP11-503K16 Signal on der(18); no split signal
18,717,972–18,718,524
9p22.1 chr9: RP11-513M16 Signal on der(18); no split signal
19,371,384–19,371,943
9p21.3 chr9: RP11-15P13 Signal on der(18); no split signal
20,182,493–20,361,132
9p21.3 chr9: MLLT3 MLLT3-gene signal on der(18); no split signal
20,344,968–20,621,872
9p21.3 chr9: SPEC p16 Deletion on der(9) and/or der(18)
21,967,751–21,975,132
9p21.3 chr9: RP11-946B6 Deletion on der(9) and/or der(18) ish 9p21.3(RP11-946B6x0)[8]
23,608,612–23,790,449
9p21.2 chr9: RP11-438B23 Signal on der(9); no split signal
27,937,615–27,944,495
18q21.32 chr18: MALT1 MALT1-gene signal on der(18); no split signal
56,338,618–56,417,370
18q21 chr18: BCL2 BCL2-gene signal on der(2); no split signal
60,985,282–60,985,899
(b)
Cytoband Location [hg19] Probe Result for derivative chromosomes
9p21.3 chr9:21,967,751–21,975,132 SPEC p16
ish 9p21.3(p16x1)[4]
nuc ish 9p21(p16x0)[64]/9p21(p16x1)[83]/
9p21(p16x2)[53]
13q14.2 chr13:48,920,000–49,140,000 LSI 13 = 𝑅𝐵1
nuc ish 13q14.2(𝑅𝐵1x0)[36]/
13q14.2(𝑅𝐵1x1)[43]/
13q14.2(𝑅𝐵1x2)[121]
shown in Figure 2 confirmed these suggestions. Locus
specific probes narrowed down the breakpoints as shown
in Table 1(a). Unfortunately there was no sufficient cell
pellet available to characterize the breakpoints in more
detail than listed in Table 1(a). Even though closely located
to the observed chromosomal breakpoints, direct involve-
ment of the following oncogenes was excluded using
locus specific FISH-probes for ALK in 2p23.2, MLLT3 in
9p21.3, and MALT1 and BCL2 in 18q21.33. However, MLPA
(result not shown) and aCGH (Figure 3) revealed that the
t(2;9;18) is not really balanced: a deletion in 9p21.3 includ-
ing CDKN2A/INK4A/p16, CDKN2B/INK4B/p15, andMTAP/
ARF/p14 could be found as chr9: 21,252,517–21,798,676x1
and 21,817,082–23,515,821x0 (hg19) (Figure 3; Table 1(b)).
Moreover, a deletion in 13q14.2 was detected as chr13:
48,982,000–49,062,000x1 (hg19, Figure 3). FISH showed a
mosaic condition of mixed heterozygous and homozygous
deletion of 9p21.3 and 13q14.2 (Table 1(b)).
4. Discussion
Chromosomal translocations are considered to be the pri-
mary cause of leukemia for both acute and chronic phase. In
this study, we retrospectively identified previously undetected
balanced and unbalanced chromosomal and subchromoso-
mal changes by application of molecular cytogenetics includ-
ing FISH-banding, locus-specific FISH-probes, and aCGH
plus MLPA. FISH-banding, especially mMCB, allows the
identification of balanced and unbalanced inter- and intra-
chromosomal rearrangements of the whole human karyotype
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Figure 1: Application of mMCB showed no normal karyotype
but derivative chromosomes 2, 9, 10, 14, and 18 (arrows). mMCB
results are shown as overlay of three of the six used color channels.
Evaluation was done as previously reported [10] using all 6 color
channels and pseudocoloring. Breakpoints were determined as
2p23.2, 9p21.3, 10q24, 14q11, and 18q21.33.
in one single experiment [10]. It might be indicated to apply
mMCBor comparable FISH-banding approaches routinely in
T-ALL cases exhibiting poor quality of the metaphase, that
is, not well spreading ones with chromosomes appearing as
fuzzy with indistinct margins [16, 17].
In this study one well-known and one yet unreported
balanced translocation event were identified for a T-ALL
as t(10;14)(q24;q11) and t(2;9;18)(p23.2;p21.3;q21.33), respec-
tively. While a direct involvement of the cancer-related
oncogenes ALK in 2p23.2, MLLT3 in 9p21.3, and BCL2 in
18q21.33 could be excluded, loss of two tumor suppresser gene
loci in 9p21 and in 13q14 was found.
Data from the literature confirmed that the oncogenes
tested and located nearby the chromosomal breakpoints of
the three-way translocation were not yet found to be involved
in T-ALL: ALK located in 2p23.2 was previously detected in
a variety of B- and T-cell lymphomas and nonhematopoietic
solid tumors [18–23], the BCL2 gene is overexpressed in
lymphomas [24, 25], and theMLLT3 genewas one of themost
highly upregulated transcripts and the most common fusion
partner of MLL in de novo acute myeloid leukemia (AML)
subtype M5 and therapy-related AML [26–28]; however,
Meyer et al. [29] found that MLLT3 also plays a role in
pediatric rather than adult ALL.
In the present case, an additional chromosomal translo-
cation t(10;14)(q24;q11), known as sole abnormality in 10%
of T-ALL patients, was identified. Also it is present in 5% of
pediatric and 30% of adult T-ALL [20, 30, 31]. The TLX1 gene
at 10q24 is a transcription factor becoming overexpressed as
oncogene due to its juxtaposition to a strong promoter and
enhancer elements of the TCR loci at 14q11 [5, 32–34]. A
favorable outcome was reported in pediatric and adult T-ALL
MCB 2
MCB 9
MCB 18
Normal der(2) der(9) der(18)
(a)
wcp10
wcp14
der(14)der(10)#10 #14
(b)
Figure 2: (a) Results of aMCB probe sets for chromosomes 2, 9, and
18 are shown in pseudocolor depiction, which confirmed the char-
acterization of these three chromosomes involving rearrangement
as t(2;9;18)(p23.2;p21.3;q21.33). (b)Whole chromosomepaints (wcp)
for chromosomes 10 and 14 confirmed that the t(10;14)(q24;q11) was
independent of the t(2;9;18).
to be associatedwith the t(10;14) or TLX1 gene overexpression
[5, 20, 35].
Even though balanced rearrangements are known to be
typical for hematopoietic malignancies to date, only a limited
number of studies have used whole genome directed FISH
approaches to identify cryptic chromosomal abnormalities
in ALL patients [36–38]. Still, in ALL it is uncommon to
see three-way translocations. However, due to lowmetaphase
resolution in ALL the real incidence of three-way transloca-
tions is currently unknown.
The present report highlights that after identification
of apparently balanced chromosomal aberrations, it is still
necessary to screen for further unbalanced submicroscopic
abnormalities by molecular approaches such as MLPA and
aCGH. However, also a confirmation of the results by molec-
ular cytogenetics is necessary, as aCGH was partially mis-
classified a mix of homo- and heterozygote deletions as pure
homozygote ones.
9p21.3 deletions, which lead to the loss of CDKN2A/
INK4A/p16, CDKN2B/INK4B/p15, and MTAP/ARF/p14
tumor suppressor genes expression, are the most predomi-
nant aberrations seen in precursor B-cell ALL (∼20% of the
cases) and T-ALL (>60% of the case) [39–42]. Besides also
a deletion of RB1 gene resulting in inactivation of another
tumor suppressor gene expression was identified. RB1 is
rarely reported to be deleted in T-ALL. In contrast, deletion
of RB1 has been detected in 30% of B-ALL and nearly to 60%
in B-CLL cases [43, 44]. Thus, RB1 pathway was identified as
potential targets for therapy of ALL [45, 46].
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Figure 3: aCGH confirmed deletions in 9p21.3 and 13q14.2 (arrows) detected initially byMLPA (result not shown). FISH confirmed presence
of these deletions in metaphase and/or interphase. Examples for heterozygote deletions of 9p21.3 and 13q14.2 are depicted; probes specific for
the corresponding tumor suppressor genes were labeled in red; centromeric probe for chromosome 9 (D9Z3) was labeled in green.
5. Conclusion
In conclusion, we report a case of T-ALL with complex chro-
mosomal aberrations. Even if at time of diagnosis the deletion
on 9p21.3 would have been detected and accordingly treated,
it remains unclear what influence the other tumor suppres-
sors and oncogenes (possibly) activated by the complex rear-
rangements would have had for the clinical outcome. Overall,
the present case stresses the necessity to study hematological
malignancies by different means to get a comprehensive pic-
ture of the genetic changes in connection with the acquired
disease, as aCGH or MLPA alone would only have identified
the imbalanced rearrangements, while molecular cytogenet-
ics predominantly gave hints on the presence of balanced
rearrangements.
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